Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?

被引：0
|
作者：
Coriu, Daniel [1 ]
Stancioaica, Maria -Camelia [1 ]
机构：
[1] Carol Davila Univ Med & Pharm, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 01期
关键词：
D O I：
10.3324/haematol.2023.283652
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 10
页数：3
相关论文
共 50 条
  • [41] Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept
    Fattizzo, Bruno
    Marchetti, Alfredo
    Zaninoni, Anna
    Lionetti, Marta
    Riva, Marta
    Rizzo, Lorenzo
    Pettine, Loredana
    Galli, Nicole
    Mazzon, Federico
    Fermo, Elisa
    Maeda, Akihiro
    Marella, Alessio
    Da Via, Matteo Claudio
    Passamonti, Francesco
    Bolli, Niccolo
    Barcellini, Wilma
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : E345 - E348
  • [42] ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES
    Cerchione, C.
    Alfinito, F.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Cerciello, G.
    Musuraca, G.
    Lucchesi, A.
    Di Battista, V.
    Cangini, D.
    Giannini, M. B.
    Ronconi, S.
    Ceccolini, M.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2020, 105 : S76 - S76
  • [43] Clinical responses to alemtuzumab in six patients with low-risk myelodysplastic syndromes and aplastic anemia
    Neukirchen, J.
    Strupp, C.
    Kuendgen, A.
    Tsamaloukas, A.
    Haas, R.
    Germing, U.
    ONKOLOGIE, 2012, 35 : 148 - 149
  • [44] Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)
    Cerchione, Claudio
    Alfinito, Fiorella
    Giannini, Benedetta Maria
    Pane, Fabrizio
    Musuraca, Gerardo
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S318 - S318
  • [45] Is Luspatercept the New Standard of Care in Transfusion- Dependent Low-Risk Myelodysplastic Syndromes?
    Garcia-Manero, Guillermo
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (08) : 367 - 369
  • [46] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    Viniou, N
    Terpos, E
    Galanopoulos, A
    Kritikou-Griva, E
    Akel, S
    Michalis, E
    Apostolidou, E
    Georgiadou, D
    Kouraklis, A
    Parharidou, A
    Kokkini, G
    Symeonidis, A
    Anagnostopoulos, NI
    Christakis, JI
    Tasiopoulou, A
    Loukopoulos, D
    Yataganas, X
    ANNALS OF HEMATOLOGY, 2002, 81 (04) : 182 - 186
  • [47] Pathogenesis of iron overload in myelodysplastic syndromes and the debate on iron chelation in low-risk MDS
    Shenoy, Niraj
    Verma, Amit
    Ginzburg, Yelena
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S85 - S85
  • [48] SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
    Cerchione, C.
    Alfinito, F.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Cerciello, G.
    Musuraca, G.
    Lucchesi, A.
    Di Battista, V.
    Cangini, D.
    Giannini, M. B.
    Ronconi, S.
    Ceccolini, M.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2022, 107 : 65 - 66
  • [49] Evidence for a role of mitochondrial signaling in apoptosis in low-risk myelodysplastic syndromes (RA and RARS).
    Tehranchi, R
    Fadeel, B
    Forsblom, AM
    Christensson, B
    Zhivotovsky, B
    Hellstrom-Lindberg, E
    BLOOD, 2001, 98 (11) : 730A - 730A
  • [50] Limited efficacy of azacitidine, with or without erythropoietin, in low-risk myelodysplastic syndromes resistant to erythropoietin
    Eclache, Virginie
    HEMATOLOGIE, 2016, 22 (05): : 308 - +
12345